Perceptive Advisors
Latest statistics and disclosures from Perceptive Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PRAX, CELC, ASND, ROIV, CNTA, and represent 35.20% of Perceptive Advisors's stock portfolio.
- Added to shares of these 10 stocks: ASND (+$103M), CNTA (+$93M), RLAY (+$78M), MRNA (+$51M), BCRX (+$41M), IONS (+$38M), DAWN (+$38M), SYRE (+$36M), DMRA (+$32M), RVMD (+$25M).
- Started 20 new stock positions in DMRA, SRZN, CORT, MRNA, STRO, NMRA, EDSA, OCUL, PHAT, APLS. AgomAb Therapeutics NV, EOLS, EVMN, XGN, ADPT, RVMD, TWST, DAWN, IONS, DBVT.
- Reduced shares in these 10 stocks: , , ACLX (-$96M), BSX (-$93M), , Astria Therapeutics (-$85M), APGE (-$67M), DHR (-$46M), BLTE (-$42M), VRDN (-$37M).
- Sold out of its positions in ALDX, FOLD, AQST, ACLX, Astria Therapeutics, BIIB, BDSX, BSX, CVS, CAPR.
- Perceptive Advisors was a net seller of stock by $-680M.
- Perceptive Advisors has $5.1B in assets under management (AUM), dropping by -8.78%.
- Central Index Key (CIK): 0001224962
Tip: Access up to 7 years of quarterly data
Positions held by Perceptive Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Perceptive Advisors
Perceptive Advisors holds 94 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Praxis Precision Medicines I Com New (PRAX) | 12.8 | $656M | +2% | 2.0M | 322.19 |
|
| Celcuity (CELC) | 7.0 | $357M | 3.1M | 114.14 |
|
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 6.8 | $350M | +41% | 1.5M | 228.73 |
|
| Roivant Sciences SHS (ROIV) | 4.5 | $230M | +3% | 8.3M | 27.70 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 4.1 | $209M | +80% | 5.3M | 39.72 |
|
| Rhythm Pharmaceuticals (RYTM) | 4.0 | $206M | -6% | 2.4M | 86.97 |
|
| Spyre Therapeutics Com New (SYRE) | 3.7 | $191M | +23% | 3.8M | 50.44 |
|
| Nuvalent Inc-a (NUVL) | 3.2 | $162M | -5% | 1.6M | 102.45 |
|
| Edgewise Therapeutics (EWTX) | 2.7 | $139M | 4.4M | 31.50 |
|
|
| Protagonist Therapeutics (PTGX) | 2.5 | $130M | -8% | 1.2M | 105.40 |
|
| Apogee Therapeutics (APGE) | 2.5 | $130M | -33% | 1.5M | 84.17 |
|
| Travere Therapeutics (TVTX) | 2.4 | $123M | -3% | 4.1M | 29.71 |
|
| Amylyx Pharmaceuticals (AMLX) | 2.3 | $115M | 8.3M | 13.90 |
|
|
| Immatics SHS (IMTX) | 2.0 | $102M | 10M | 9.84 |
|
|
| Relay Therapeutics (RLAY) | 1.9 | $97M | +412% | 9.8M | 9.95 |
|
| Inhibrx Biosciences (INBX) | 1.9 | $97M | 1.4M | 67.23 |
|
|
| Meiragtx Holdings (MGTX) | 1.7 | $89M | 10M | 8.65 |
|
|
| Zymeworks Del (ZYME) | 1.7 | $88M | +7% | 3.5M | 25.04 |
|
| Solid Biosciences Com New (SLDB) | 1.7 | $86M | 12M | 7.20 |
|
|
| Dyne Therapeutics (DYN) | 1.7 | $85M | +34% | 4.7M | 18.13 |
|
| BioCryst Pharmaceuticals (BCRX) | 1.4 | $71M | +135% | 7.4M | 9.52 |
|
| Oruka Therapeutics (ORKA) | 1.3 | $68M | -5% | 1.4M | 49.05 |
|
| CryoLife (AORT) | 1.2 | $60M | -4% | 1.6M | 36.62 |
|
| Nurix Therapeutics (NRIX) | 1.1 | $58M | +4% | 3.7M | 15.50 |
|
| Moderna Put Option (MRNA) | 1.0 | $51M | NEW | 1.0M | 50.80 |
|
| Nautilus Biotechnology (NAUT) | 1.0 | $49M | 13M | 3.88 |
|
|
| Cytomx Therapeutics (CTMX) | 0.9 | $48M | +4% | 10M | 4.70 |
|
| Alto Neuroscience Com Shs (ANRO) | 0.9 | $45M | +12% | 2.0M | 22.48 |
|
| Engene Holdings (ENGN) | 0.8 | $40M | 5.8M | 6.81 |
|
|
| Immunovant (IMVT) | 0.8 | $40M | -19% | 1.6M | 24.84 |
|
| Intuitive Surgical Com New (ISRG) | 0.8 | $39M | -2% | 85k | 460.99 |
|
| Ionis Pharmaceuticals (IONS) | 0.7 | $38M | NEW | 504k | 75.09 |
|
| Day One Biopharmaceuticals I (DAWN) | 0.7 | $38M | NEW | 1.8M | 21.44 |
|
| Abivax Sa Sponsored Ads (ABVX) | 0.7 | $37M | -28% | 329k | 111.35 |
|
| Corvus Pharmaceuticals (CRVS) | 0.7 | $34M | +231% | 2.3M | 14.63 |
|
| Repligen Corporation (RGEN) | 0.6 | $33M | -11% | 281k | 117.82 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 0.6 | $32M | 170k | 189.05 |
|
|
| Damora Therapeutics Com New (DMRA) | 0.6 | $32M | NEW | 1.2M | 25.90 |
|
| X4 Pharmaceuticals Com New (XFOR) | 0.5 | $28M | +6% | 6.7M | 4.13 |
|
| Guardant Health (GH) | 0.5 | $28M | +87% | 300k | 92.37 |
|
| Bright Minds Biosciences Com New (DRUG) | 0.5 | $28M | -15% | 378k | 72.97 |
|
| Adagio Therapeutics (IVVD) | 0.5 | $27M | -4% | 21M | 1.30 |
|
| Sionna Therapeutics (SION) | 0.5 | $26M | -44% | 658k | 40.09 |
|
| Axsome Therapeutics (AXSM) | 0.5 | $25M | 150k | 169.02 |
|
|
| Revolution Medicines (RVMD) | 0.5 | $25M | NEW | 259k | 97.25 |
|
| Sab Biotherapeutics Com New (SABS) | 0.5 | $25M | +700% | 6.4M | 3.83 |
|
| Belite Bio Sponsored Ads (BLTE) | 0.5 | $24M | -63% | 152k | 159.44 |
|
| Tenax Therapeutics Com New (TENX) | 0.5 | $23M | +229% | 1.4M | 15.99 |
|
| Axogen (AXGN) | 0.5 | $23M | -11% | 697k | 33.13 |
|
| Miragen Therapeutics (VRDN) | 0.4 | $23M | -61% | 1.2M | 19.56 |
|
| Health Sciences Acq Corp 2 (OBIO) | 0.4 | $21M | 5.0M | 4.25 |
|
|
| Rapport Therapeutics (RAPP) | 0.4 | $21M | 674k | 31.29 |
|
|
| Dbv Technologies S A Sponsored Ads (DBVT) | 0.4 | $20M | NEW | 964k | 20.89 |
|
| Athira Pharma (LONA) | 0.4 | $19M | 1.9M | 10.28 |
|
|
| Anteris Technologies Global (AVR) | 0.4 | $19M | +104% | 3.4M | 5.55 |
|
| Sutro Biopharma Com Shs (STRO) | 0.3 | $18M | NEW | 715k | 24.91 |
|
| Tango Therapeutics (TNGX) | 0.3 | $17M | +57% | 808k | 20.92 |
|
| Contineum Therapeutics Cl A (CTNM) | 0.3 | $16M | -14% | 1.3M | 13.06 |
|
| Celcuity Note 2.750% 8/0 (Principal) | 0.3 | $16M | 6.5M | 2.44 |
|
|
| Palisade Bio (PALI) | 0.3 | $16M | -25% | 8.9M | 1.75 |
|
| Oculis Holding Ordinary Shares (OCS) | 0.3 | $13M | 494k | 26.59 |
|
|
| Irhythm Technologies (IRTC) | 0.2 | $12M | -2% | 105k | 118.02 |
|
| Adagio Med Hldgs (ADGM) | 0.2 | $11M | 9.9M | 1.11 |
|
|
| Evommune Com Shs (EVMN) | 0.2 | $10M | NEW | 448k | 22.99 |
|
| Phathom Pharmaceuticals (PHAT) | 0.2 | $10M | NEW | 925k | 11.11 |
|
| Neumora Therapeutics (NMRA) | 0.2 | $10M | NEW | 5.1M | 1.95 |
|
| Omada Health (OMDA) | 0.2 | $9.9M | -67% | 786k | 12.57 |
|
| Neurocrine Biosciences (NBIX) | 0.2 | $8.6M | -80% | 65k | 131.74 |
|
| Beta Bionics (BBNX) | 0.2 | $8.4M | +39% | 843k | 10.02 |
|
| Ocuphire Pharma (IRD) | 0.2 | $8.4M | -57% | 1.8M | 4.55 |
|
| Billiontoone Cl A (BLLN) | 0.1 | $7.2M | +26% | 92k | 78.94 |
|
| Twist Bioscience Corp (TWST) | 0.1 | $7.1M | NEW | 150k | 47.52 |
|
| Surrozen Com New (SRZN) | 0.1 | $6.7M | NEW | 229k | 29.13 |
|
| Agomab Therapeutics Nv Sponsored Ads | 0.1 | $6.3M | NEW | 600k | 10.49 |
|
| Evolus (EOLS) | 0.1 | $5.3M | NEW | 1.3M | 4.11 |
|
| Cogent Biosciences (COGT) | 0.1 | $4.7M | 121k | 38.49 |
|
|
| Ocular Therapeutix Call Option (OCUL) | 0.1 | $4.2M | NEW | 500k | 8.47 |
|
| Adma Biologics (ADMA) | 0.1 | $4.2M | -47% | 467k | 9.01 |
|
| Inhibikase Therapeutics Com New (IKT) | 0.1 | $3.9M | -57% | 2.3M | 1.68 |
|
| Crescent Biopharma (CBIO) | 0.1 | $3.8M | -54% | 207k | 18.37 |
|
| Apellis Pharmaceuticals (APLS) | 0.1 | $3.3M | NEW | 81k | 40.23 |
|
| Outset Med Com New (OM) | 0.1 | $3.2M | 833k | 3.84 |
|
|
| Edesa Biotech Com New (EDSA) | 0.1 | $2.9M | NEW | 563k | 5.23 |
|
| Adaptive Biotechnologies Cor (ADPT) | 0.0 | $2.1M | NEW | 153k | 13.88 |
|
| Avalo Therapeutics Com New (AVTX) | 0.0 | $2.1M | 140k | 14.93 |
|
|
| Connect Biopharma Hldgs SHS (CNTB) | 0.0 | $2.1M | 793k | 2.62 |
|
|
| Corcept Therapeutics Incorporated (CORT) | 0.0 | $2.0M | NEW | 50k | 40.31 |
|
| Medline Com Cl A (MDLN) | 0.0 | $1.2M | 28k | 44.50 |
|
|
| Palatin Technologies Com New (PTN) | 0.0 | $1.1M | -11% | 62k | 17.42 |
|
| Cumberland Pharmaceuticals (CPIX) | 0.0 | $640k | -42% | 197k | 3.25 |
|
| Revolution Medicines *w Exp 12/17/202 (RVMDW) | 0.0 | $448k | 250k | 1.79 |
|
|
| Exagen (XGN) | 0.0 | $345k | NEW | 115k | 3.00 |
|
| Ensysce Biosciences Com New (ENSC) | 0.0 | $47k | 87k | 0.54 |
|
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $2.7k | 167k | 0.02 |
|
Past Filings by Perceptive Advisors
SEC 13F filings are viewable for Perceptive Advisors going back to 2010
- Perceptive Advisors 2026 Q1 restated filed May 29, 2026
- Perceptive Advisors 2026 Q1 filed May 15, 2026
- Perceptive Advisors 2025 Q4 filed Feb. 17, 2026
- Perceptive Advisors 2025 Q3 filed Nov. 14, 2025
- Perceptive Advisors 2025 Q2 filed Aug. 14, 2025
- Perceptive Advisors 2025 Q1 restated filed Aug. 6, 2025
- Perceptive Advisors 2025 Q1 filed May 15, 2025
- Perceptive Advisors 2024 Q4 filed Feb. 14, 2025
- Perceptive Advisors 2024 Q3 filed Nov. 14, 2024
- Perceptive Advisors 2024 Q2 restated filed Aug. 16, 2024
- Perceptive Advisors 2024 Q2 filed Aug. 14, 2024
- Perceptive Advisors 2024 Q1 restated filed Aug. 6, 2024
- Perceptive Advisors 2024 Q1 filed May 15, 2024
- Perceptive Advisors 2023 Q4 restated filed Feb. 26, 2024
- Perceptive Advisors 2023 Q4 filed Feb. 14, 2024
- Perceptive Advisors 2023 Q3 filed Nov. 14, 2023